NKGen Biotech, Inc. (NYSE:NKGN – Get Free Report) shares dropped 2.9% on Wednesday . The company traded as low as $1.15 and last traded at $1.17. Approximately 70,593 shares traded hands during trading, a decline of 97% from the average daily volume of 2,060,171 shares. The stock had previously closed at $1.20.
NKGen Biotech Stock Performance
The stock’s 50 day simple moving average is $1.34 and its two-hundred day simple moving average is $1.67.
NKGen Biotech (NYSE:NKGN – Get Free Report) last issued its earnings results on Monday, May 20th. The company reported ($0.25) EPS for the quarter.
Institutional Investors Weigh In On NKGen Biotech
NKGen Biotech Company Profile
NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.
Featured Articles
- Five stocks we like better than NKGen Biotech
- What Do S&P 500 Stocks Tell Investors About the Market?
- Top 3 Beverage Stocks: Summer Earnings Reveal Key Trends
- Where to Find Earnings Call Transcripts
- This Financial Stock’s Earnings Signal a Buying Opportunity
- What is the Shanghai Stock Exchange Composite Index?
- Social Platform Stock Hits New Highs: Is More Growth Ahead?
Receive News & Ratings for NKGen Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NKGen Biotech and related companies with MarketBeat.com's FREE daily email newsletter.